Effect of physical exercises on gait speed in patients with Parkinson’s disease
Objective: To verify the effect of the application of physical exercises with a dual task on gait speed and the occurrence of falls in people…The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson’s disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study
Objective: This study aims to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) in patients with…Evaluating Engagement of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody to Physiological and Pathological Forms of Alpha-Synuclein for Phase 2 Dose Selection: A PBPK Modeling and Simulation Approach
Objective: To develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model to assist in the dose and dosing regimen selection of ABBV-0805 for Phase 2 studies. Background:…The Hauser Diary knowledge test as a tool to improve Rater Training Programs in Parkinson’s disease clinical trials
Objective: To identify the areas with specific training needs for Rater Training Programs (RTP) on the Hauser Diary in Parkinson’s disease (PD) clinical trials Background:…Apathy Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial
Objective: To determine frequency and predictors of improvement or worsening of apathy in participants receiving bilateral subthalamic deep brain stimulation (STN-DBS) for the treatment of…Are Mobile Persons with Parkinson Disease Necessarily More Active?
Objective: The primary aims of this study were (1) to determine in persons with Parkinson Disease (PD) the extent to which walking activity might contribute…Comparison of Antiparkinsonian Medication Initiation and Levodopa-Equivalent Daily Dose Across PPMI, STEADY-PD III, and SURE-PD3
Objective: To compare use of antiparkinsonian medications (APM) among early Parkinson disease (PD) patients across clinical study cohorts. Background: Initiation of APM is a key…LY-487,379 alleviates parkinsonism when administered as monotherapy in the MPTP-lesioned marmoset
Objective: To determine the effect of selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulation as monotherapy on parkinsonism, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Background: We…LY-487,379 enhances the anti-parkinsonian action of a low dose of L-DOPA in the MPTP-lesioned marmoset
Objective: To investigate the effect of selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulation on the anti-parkinsonian action of a low dose of…Effect of simultaneous mGlu2 positive allosteric modulation and orthosteric stimulation combined with 5-HT2A antagonism on psychosis-like behaviours, dyskinesia and parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effects of concurrent metabotropic glutamate type 2 (mGlu2) positive allosteric modulation and orthosteric stimulation combined with serotonin type 2A (5-HT2A) antagonism.…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 132
- Next Page »